

LMI070 (branaplam) in Spinal Muscular Atrophy (SMA)

A message from the Novartis branaplam team

Dear SMA community

On Thursday 12 October 2017, Novartis had a meeting with representatives from the SMA community in Berlin. The objective of the meeting was to hear the perspectives of SMA patients, their caregivers and the SMA community about living with SMA and about participating in SMA clinical trials. The SMA community representatives at the meeting came from a variety of European countries and were well-informed about diverse standards of care across these countries.

We would like to thank the SMA community representatives for the open engagement and for generously sharing their deep knowledge and expertise. The discussion was very productive and Novartis looks forward to incorporating points that we heard, to improve the experience of future clinical trials for SMA patients and their caregivers.

Best regards,

Novartis branaplam program team

